4//SEC Filing
Crombez Eric 4
Accession 0000950170-24-026635
CIK 0001515673other
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 8:10 PM ET
Size
11.8 KB
Accession
0000950170-24-026635
Insider Transaction Report
Form 4
Crombez Eric
EVP and Chief Medical Officer
Transactions
- Award
Common Stock
2024-03-01+19,400→ 49,912 total - Sale
Common Stock
2024-03-01$53.76/sh−1,238$66,555→ 48,927 total - Award
Stock Option (Right to Buy)
2024-03-01+34,200→ 34,200 totalExercise: $53.69Exp: 2034-03-01→ Common Stock (34,200 underlying) - Award
Stock Option (Right to Buy)
2024-03-01+2,351→ 2,351 totalExercise: $67.37Exp: 2027-03-01→ Common Stock (2,351 underlying)
Footnotes (6)
- [F1]Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
- [F2]Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
- [F3]Includes 253 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on October 31, 2023.
- [F4]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- [F5]On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
- [F6]On March 1, 2022, the Reporting Person was granted an option to purchase 2,351 shares of common stock. The option vests upon the achievement of specified performance criteria. Upon achievement of the performance criteria, 1/3 of the option vests on the date of certification by the Issuer's compensation committee of achievement of the performance criteria, 1/3 of the option vests on March 1, 2024 and 1/3 of the option vests on March 1, 2025. On March 1, 2024, the Issuer's compensation committee certified achievement of the performance criteria for the option, resulting in the vesting of the option of 1,568 shares on that date.
Documents
Issuer
Ultragenyx Pharmaceutical Inc.
CIK 0001515673
Entity typeother
Related Parties
1- filerCIK 0001653052
Filing Metadata
- Form type
- 4
- Filed
- Mar 4, 7:00 PM ET
- Accepted
- Mar 5, 8:10 PM ET
- Size
- 11.8 KB